Blueprint Medicines appoints Habib Dable to its board of directors

CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who served as President and CEO of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, business growth and organizational scale at global pharmaceutical and biotechnology companies. emerging.

To print

“Habib’s experience leading complex global organizations will be extremely valuable as Blueprint Medicines drives our next phase of transformational growth,” said Kate Haviland, Chief executive officer. “We are delighted to welcome his significant expertise and perspective to our Board of Directors.”

“Blueprint Medicines has an impressive track record for a company of its size and age; even more impressive are the potential development and commercialization opportunities that lie ahead,” said Dable. “I look forward to working with the high caliber team at Blueprint to seize these opportunities and continue to bring the promise of precision medicine to large patient populations.”

Mr. Dable joins Blueprint Medicines with significant leadership, growth and business experience gained over nearly 30 years in the biopharmaceutical industry. More recently, as CEO of Acceleron, Mr. Dable generated over $10 billion in shareholder value during his 5 years tenure as CEO before successfully transitioning to Merck following its acquisition. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility and geographic footprint, including Chairman of US Pharmaceuticals; Executive Vice President, Global Head of Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Leader, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. Most recently, Mr. Dable served on the board of directors of the Biotechnology Innovation Organization (BIO). Mr. Dable holds a BBA in Marketing and Finance and an MBA from University of New Brunswick.

About Blueprint Medications

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. By applying a precise yet agile approach, we create drugs that selectively target genetic factors, with the goal of staying ahead through disease stages. Since 2011, we have leveraged our research platform, including our molecular targeting expertise and world-class drug design capabilities, to rapidly and reproducibly translate science into a wide range of precision therapies. Today, we provide approved medicines directly to patients in United States and Europe, and we are advancing several programs globally for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, objectives and anticipated milestones, plans for business and direction of Blueprint Medicines. The words “aim”, “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, ” believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. ‘identification. All forward-looking statements contained in this report are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ materially. of those expressed or implied by the forward-looking statements. contained in this report, including but not limited to the risks and uncertainties associated with the impact of the COVID-19 pandemic on Blueprint Medicines business, operations, strategy, objectives and planned milestones , including Blueprint Medicines’ ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, deliver current or future drug candidates, deliver current or future approved products commercially, and to launch, market and sell current or future approved products; Blueprint Medicines’ ability and plans to continue to establish and expand a commercial infrastructure and to successfully launch, market and sell current or future approved products; Blueprint Medicines’ ability to successfully expand approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in other geographies in the future; delay in any ongoing or planned clinical trials or development of Blueprint Medicines’ current or future drug candidates; advancing Blueprint Medicines from multiple early-stage efforts; the ability of Blueprint Medicines to successfully demonstrate the safety and efficacy of its drug candidates and to obtain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results of Blueprint Medicines’ drug candidates, which may not support the further development of these drug candidates, either as monotherapies or in combination with other agents, or may impact the expected timing of data or regulatory submissions; timing of initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protections for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it develops; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines’ ability to successfully expand its operations, research platform and pipeline of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines’ ability to realize the expected benefits of its executive transition plan; and the success of Blueprint Medicines’ current and future collaborations, acquisitions, partnerships or licensing agreements. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent annual report. Blueprint Medicines on Form 10-K, as supplemented by its most recent quarterly report on Form 10-Q and any other filings Blueprint Medicines has made or may make with the SEC in the future. All forward-looking statements contained in this report represent the views of Blueprint Medicines only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines expressly disclaims any obligation to update forward-looking statements.

Trademarks

Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-appointments-habib-dable-to-its-board-of-directors-301574460.html

SOURCE Blueprint Medicines Corporation

>

Leave a Comment